2015
DOI: 10.1016/j.euroneuro.2015.01.016
|View full text |Cite
|
Sign up to set email alerts
|

Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
71
0
3

Year Published

2015
2015
2023
2023

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 114 publications
(75 citation statements)
references
References 615 publications
(491 reference statements)
1
71
0
3
Order By: Relevance
“…Pharmacological management of depression currently involves drugs that often target the monoamine transporters, which include selective reuptake inhibitors for serotonin (5-hydroxytryptamine, 5-HT) (SSRIs), noradrenaline (NA) inhibitors (NRIs), or a combination of both (SNRIs) (8)(9)(10), as well as a number of other medications (11). However, the therapeutic efficacy of these antidepressants is hampered by a slow onset of action, a limited response rate, and considerable side effects (12,13).…”
mentioning
confidence: 99%
“…Pharmacological management of depression currently involves drugs that often target the monoamine transporters, which include selective reuptake inhibitors for serotonin (5-hydroxytryptamine, 5-HT) (SSRIs), noradrenaline (NA) inhibitors (NRIs), or a combination of both (SNRIs) (8)(9)(10), as well as a number of other medications (11). However, the therapeutic efficacy of these antidepressants is hampered by a slow onset of action, a limited response rate, and considerable side effects (12,13).…”
mentioning
confidence: 99%
“…A better knowledge of pathophysiology is surely a step for the identification of new pharmacological targets, perhaps beyond the symptomatic treatment (Millan et al, 2015). At a time where the pathology-to-drug discovery approach is in expansion, our certitudes regarding the treatment of Parkinson's disease and the mechanism of action of the lead antiparkinsonian treatment L-DOPA are disappearing.…”
Section: Neuropharmacological Journey In Monoaminergic Fieldsmentioning
confidence: 99%
“…Medicinal chemistry has detected some newer compounds that affect identified molecular targets and additional monoaminergic targets are still being investigated. Although monoaminergic systems have a pivotal role in the effect of many existing medicines, there is a need for further developments, as additional targets have been identified that could be as interesting as monoamines (Millan et al, 2015b). …”
Section: Introductionmentioning
confidence: 99%
“…The complexity of these circuits may lead to the proposed use of either agonists or antagonists for correcting the same diseases (Di Giovanni and De Deurwaerdère, 2016). There is a growing body of evidence demonstrating that most neuropsychiatric disorders are multifactorial and that an action on a single target is elusive both in terms of symptomatic and curative treatments (Millan et al, 2015a,b). Increased understanding of the mechanisms involved in such diseases led to the use of combinations of drugs targeting distinct receptors/enzymes or to the development of multi-target drugs.…”
Section: Introductionmentioning
confidence: 99%